Biotechnology and Pharmaceuticals

March 08, 2018

Companies covered: Spero Therapeutics, Inc. (NASDAQ:SPRO), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Pfizer, Inc. (NYSE:PFE), AbbVie Inc. (NYSE:ABBV), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Cellectis S.A. (NASDAQ:CLLS), Celsion Corporation (NASDAQ:CLSN), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Amgen Inc. (NASDAQ:AMGN), Gilead Sciences, Inc. (NASDAQ:GILD), Summit Therapeutics PLC (NASDAQ:SMMT), Spark Therapeutics, Inc. (NASDAQ:ONCE), Sage Therapeutics, Inc. (NASDAQ:SAGE), Achaogen Inc (NASDAQ:AKAO), Nabriva Therapeutics plc (NASDAQ:NBRV), Race Oncology Ltd. (ASX:RAC), Soligenix, Inc. (NASDAQ:SNGX), TiGenix (NASDAQ:TIG), Merck & Company, Inc. (NYSE:MRK), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), CRISPR Therapeutics AG (NASDAQ:CRSP), RXI Pharmaceuticals Corporation (NASDAQ:RXII), Oncolytics Biotech, Inc. (USA) (OTCMKTS:ONCYF), Cardiome Pharma Corporation (NASDAQ:CRME), Checkpoint Therapeutics Inc (NASDAQ:CKPT), Resverlogix Corp. (OTCMKTS:RVXCF), Illumina, Inc. (NASDAQ:ILMN), Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Buy ($175)